About Event:

The 2025 Nebraska Congress on Hematologic Malignancies: Recent Advances and Cellular Therapy is a CME-accredited, in-person hematology conference featuring leading hematology experts. Expert faculty will place recent s into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest s in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. LEARNING OBJECTIVES -Review recent s & discuss their applications in clinical settings. -Choose new therapeutic options for treating benign and malignant hematologic disorders, understanding appropriate indications and contraindications to these therapeutic approaches. -Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology. -Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and hematology patients. -Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.